MX2024010674A - Compuestos de quinolina antagonistas de cgas. - Google Patents
Compuestos de quinolina antagonistas de cgas.Info
- Publication number
- MX2024010674A MX2024010674A MX2024010674A MX2024010674A MX2024010674A MX 2024010674 A MX2024010674 A MX 2024010674A MX 2024010674 A MX2024010674 A MX 2024010674A MX 2024010674 A MX2024010674 A MX 2024010674A MX 2024010674 A MX2024010674 A MX 2024010674A
- Authority
- MX
- Mexico
- Prior art keywords
- quinoline
- antagonist compounds
- cgas
- compounds
- cgas antagonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263315968P | 2022-03-02 | 2022-03-02 | |
| US202363478467P | 2023-01-04 | 2023-01-04 | |
| PCT/US2023/063623 WO2023168367A1 (en) | 2022-03-02 | 2023-03-02 | QUINOLINE cGAS ANTAGONIST COMPOUNDS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024010674A true MX2024010674A (es) | 2024-11-08 |
Family
ID=85781707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010674A MX2024010674A (es) | 2022-03-02 | 2024-08-30 | Compuestos de quinolina antagonistas de cgas. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US12281078B2 (https=) |
| EP (1) | EP4486734A1 (https=) |
| JP (1) | JP2025507820A (https=) |
| KR (1) | KR20250004639A (https=) |
| CN (1) | CN119137112A (https=) |
| AU (1) | AU2023228915A1 (https=) |
| CA (1) | CA3253386A1 (https=) |
| IL (1) | IL315346A (https=) |
| MX (1) | MX2024010674A (https=) |
| TW (1) | TW202342021A (https=) |
| WO (1) | WO2023168367A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230062845A (ko) | 2020-09-03 | 2023-05-09 | 이뮨센서 테라퓨틱스, 인코포레이티드 | 퀴놀린 cgas 길항제 화합물 |
| CN119137112A (zh) | 2022-03-02 | 2024-12-13 | 免疫传感器治疗股份有限公司 | 喹啉cGAS拮抗剂化合物 |
| WO2026050765A1 (en) | 2024-08-30 | 2026-03-05 | Immunesensor Therapeutics, Inc. | Solid forms and salts of a quinoline cgas antagonist compound |
| WO2026057087A1 (zh) * | 2024-09-14 | 2026-03-19 | 杭州英创医药科技有限公司 | 作为cGAS抑制剂的化合物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3542785A (en) * | 1967-05-15 | 1970-11-24 | Ciba Geigy Corp | 2-hydroxy-4-aryl-quinolines |
| US3668207A (en) * | 1970-01-22 | 1972-06-06 | Ciba Geigy Corp | 2-amino-4-aryl-quinolines |
| WO2004002960A1 (en) * | 2002-06-27 | 2004-01-08 | Schering Aktiengesellschaft | Substituted quinoline ccr5 receptor antagonists |
| AU2008303602A1 (en) | 2007-09-27 | 2009-04-02 | F. Hoffmann-La Roche Ag | Quinoline derivatives as 5HT5A receptor antagonists |
| JP2019501904A (ja) * | 2015-12-14 | 2019-01-24 | ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ | Ｄｎａメチルトランスフェラーゼの阻害剤としての２，４，６，７−四置換キノリン化合物 |
| CN109111426B (zh) | 2017-06-23 | 2021-12-14 | 中国科学院上海药物研究所 | 一类稠合双环杂芳基或芳基化合物，及其用途 |
| IL302338B2 (en) | 2017-09-08 | 2024-10-01 | Univ Leland Stanford Junior | Enpp1 inhibitors and their use for the treatment of cancer |
| WO2019241787A1 (en) | 2018-06-15 | 2019-12-19 | The Regents Of The University Of Colorado A Body Corporate | Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use |
| US12064433B2 (en) | 2018-07-27 | 2024-08-20 | Arcus Biosciences, Inc. | Pyridone A2R antagonists |
| EP3620164A1 (en) * | 2018-09-05 | 2020-03-11 | Genoscience Pharma SAS | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases |
| WO2020142735A1 (en) | 2019-01-04 | 2020-07-09 | BellBrook Labs | Inhibitors of cgas activity as therapeutic agents |
| EP4076667A1 (en) | 2019-12-20 | 2022-10-26 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CN115209883B (zh) | 2020-01-20 | 2025-05-20 | 新月生物科学 | 新型细胞代谢调节化合物及其用途 |
| JP2023532998A (ja) | 2020-07-06 | 2023-08-01 | クレセンタ バイオサイエンシズ | 新規細胞代謝調節化合物およびそのウイルス性疾患の治療のための使用 |
| KR20230062845A (ko) | 2020-09-03 | 2023-05-09 | 이뮨센서 테라퓨틱스, 인코포레이티드 | 퀴놀린 cgas 길항제 화합물 |
| CN119137112A (zh) | 2022-03-02 | 2024-12-13 | 免疫传感器治疗股份有限公司 | 喹啉cGAS拮抗剂化合物 |
-
2023
- 2023-03-02 CN CN202380037098.5A patent/CN119137112A/zh active Pending
- 2023-03-02 EP EP23714185.8A patent/EP4486734A1/en active Pending
- 2023-03-02 KR KR1020247032755A patent/KR20250004639A/ko active Pending
- 2023-03-02 WO PCT/US2023/063623 patent/WO2023168367A1/en not_active Ceased
- 2023-03-02 IL IL315346A patent/IL315346A/en unknown
- 2023-03-02 JP JP2024551891A patent/JP2025507820A/ja active Pending
- 2023-03-02 AU AU2023228915A patent/AU2023228915A1/en active Pending
- 2023-03-02 CA CA3253386A patent/CA3253386A1/en active Pending
- 2023-03-02 TW TW112107684A patent/TW202342021A/zh unknown
- 2023-03-02 US US18/177,732 patent/US12281078B2/en active Active
- 2023-07-17 US US18/353,718 patent/US12091387B2/en active Active
-
2024
- 2024-08-30 MX MX2024010674A patent/MX2024010674A/es unknown
-
2025
- 2025-02-27 US US19/066,046 patent/US20260042737A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023228915A1 (en) | 2024-09-19 |
| US20240002346A1 (en) | 2024-01-04 |
| US20230357158A1 (en) | 2023-11-09 |
| TW202342021A (zh) | 2023-11-01 |
| CN119137112A (zh) | 2024-12-13 |
| KR20250004639A (ko) | 2025-01-08 |
| CA3253386A1 (en) | 2023-09-07 |
| JP2025507820A (ja) | 2025-03-21 |
| US12091387B2 (en) | 2024-09-17 |
| EP4486734A1 (en) | 2025-01-08 |
| IL315346A (en) | 2024-11-01 |
| US12281078B2 (en) | 2025-04-22 |
| US20260042737A1 (en) | 2026-02-12 |
| WO2023168367A1 (en) | 2023-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202304064B (en) | Quinoline cgas antagonist compounds | |
| MX2024010674A (es) | Compuestos de quinolina antagonistas de cgas. | |
| PH12021550992A1 (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
| MX2022012178A (es) | Compuestos, composiciones farmaceuticas y metodos para la preparacion de compuestos y para su uso. | |
| EP4523755A3 (en) | Quinazoline derivatives as antitumor agents | |
| PH12022550015A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2018003179A (es) | Terapia de combinación con cenicriviroc para el tratamiento de fibrosis. | |
| MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| MX2020010568A (es) | Derivados de urea ciclica fusionada como antagonista de crhr2. | |
| PH12020500099A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor | |
| PH12022551468A1 (en) | Compounds active towards nuclear receptors | |
| PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
| MX2022007265A (es) | Compuestos activos frente a receptores nucleares. | |
| JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
| WO2018027084A3 (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer | |
| MX2024013184A (es) | Metodos y composiciones para tratar apnea del sue?o | |
| MX2020007559A (es) | Formulaciones farmaceuticas. | |
| MX2024012565A (es) | Composiciones farmaceuticas de mosunetuzumab y metodos de uso | |
| PH12021553177A1 (en) | Pharmaceutical composition for treating tumor | |
| MX394957B (es) | Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1". | |
| PH12021550143A1 (en) | Pyridopyrimidines as histamine h4-receptor inhibitors | |
| AU2016407426A1 (en) | Triple combination of pure 5-HT6 receptor antagonists, Acetylcholinesterase inhibitors and NMDA receptor antagonist |